Showing results (31-40 of 72) with videos related to
Sort By:
Pageof 8
Clinical and Translational Science|August 5, 2025
Model-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib DevelopmentSumit Bhatnagar, Sven Stodtmann, Yuli Qian, et al.Clinical Pharmacology in Drug Development|April 25, 2018
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 TrialsMohamed-Eslam F Mohamed, Jiewei Zeng, Patrick J Marroum, et al.Knee Surgery & Related Research|July 15, 2020
All types of component malrotation affect the early patient-reported outcome measures after total knee arthroplastyMohammad Kamal Abdelnasser, Mohamed Eslam Elsherif, Hatem Bakr, et al.Clinical Pharmacokinetics|April 5, 2019
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical TrialsBen Klünder, Rajendar K Mittapalli, Mohamed-Eslam F Mohamed, et al.Clinical Pharmacokinetics|December 26, 2022
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis PatientsAna Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, et al.Clinical Pharmacology in Drug Development|June 10, 2021
Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy SubjectsMohamed-Eslam F Mohamed, Sheryl Coppola, Tian Feng, et al.Journal of Clinical Pharmacology|January 12, 2019
Characterization of the Effect of Renal Impairment on Upadacitinib PharmacokineticsMohamed-Eslam F Mohamed, Sheryl Trueman, Tian Feng, et al.Journal of Clinical Pharmacology|April 12, 2019
Characterization of the Effect of Hepatic Impairment on Upadacitinib PharmacokineticsSheryl Trueman, Mohamed-Eslam F Mohamed, Tian Feng, et al.Clinical Pharmacokinetics|April 16, 2015
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safetyAhmed A Othman, Krai Chatamra, Mohamed-Eslam F Mohamed, et al.Clinical Pharmacology and Therapeutics|July 10, 2024
Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's DiseaseSumit Bhatnagar, Louisa Schlachter, Doerthe Eckert, et al.Pageof 8